Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Brovana
(United States) [Available]Synonyms :
arformoterol
Class :
Drugs for asthma and COPD & Bronchodilators (Beta2-agonists/ Adrenergic agonists)
Dosage Forms & Strengths
Nebulization solution, Inhalation:
15 mcg/2 ml
Chronic Obstructive Pulmonary Disease (COPD)
15
mcg
oral inhalation twice a day
may decrease the therapeutic effect when combined with methacholine
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with other beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
beta2 agonist bronchodilation may be reduced with beta2 blockers
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
When used with levobetaxolol, arformoterol's therapeutic effectiveness may be diminished
Combining arformoterol with pranlukast may cause a reduction in the arformoterol’s metabolism
arformoterol has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
Combining tegafur with arformoterol can reduce tegafur’s metabolism
When arformoterol is used together with fluconazole, this leads to reduction in the arformoterol metabolism
tinidazole has the potential to reduce the rate of excretion of arformoterol, potentially leading to an elevation in level of serum
When ponesimod is used together with arformoterol, this leads to enhanced risk or seriousness of bradycardia
When arformoterol is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
may increase the hypokalemic effect when combined with thiazide diuretics
may increase the hypokalemic effect when combined with thiazide diuretics
When arformoterol is used together givinostat, this leads to enhanced risk or severity of Qtc prolongation
arformoterol leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefpirome leads to a reduction in the rate of excretion of arformoterol which leads to increased level of serum
arformoterol leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
arformoterol leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
arformoterol leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
arformoterol leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
arformoterol: it may increase the risk of hypokalemia with oxtriphylline
arformoterol: it may decreased the serum concentration of CNS depressants
arformoterol: it may decreased the serum concentration of CNS depressants
arformoterol: it may decreased the serum concentration of CNS depressants
arformoterol: it may decreased the serum concentration of CNS depressants
arformoterol: it may decreased the serum concentration of CNS depressants
arformoterol may decrease the excretion rate of almasilate, leading to higher serum levels
When arformoterol is used together with diazoxide, this leads to reduction in diazoxide’s antihypertensive effects
QTc interval is increased both by lenvatinib and arformoterol.
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when used together, entrectinib and arformoterol both increase the QTc interval
midostaurin and arformoterol, when used simultaneously, increase the QTc level
when both drugs are combined, there may be an increase in QTC interval
eprosartan/hydrochlorothiazideÂ
may increase the toxic effect of thiazide and thiazide like diuretics
moexipril/hydrochlorothiazideÂ
may increase the hypokalaemia effect of thiazide and thiazide like diuretics
may have an increasingly adverse effect when combined with atosiban
atomoxetine: they may increase the tachycardic effect of Beta2-Agonists
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
hypokalemic effects of thiazide-like derivatives can be increased with beta2 agonists
hypokalemic effects of thiazide-like derivatives can be increased with beta2 agonists
hypokalemic effects of thiazide-like derivatives can be increased with beta2 agonists
hypokalemic effects of thiazide-like derivatives can be increased with beta2 agonists
adverse effects of beta2 agonists are increased with tricyclic antidepressants
the risk of hypertension may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the antihypertensive activity of Remikiren may be reduced
When arformoterol is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
the hazard or seriousness of QTc prolongation can be heightened when arformoterol is combined with digitoxin
Action:Â
Arformoterol is a long-acting beta-2 adrenergic agonist (LABA) and the (R,R)-enantiomer of formoterol, which is the pharmacologically active component responsible for bronchodilation. It works by selectively stimulating beta-2 receptors in the smooth muscle of the airways, leading to relaxation of bronchial muscles and resulting in prolonged bronchodilation. Â
Spectrum:Â
Arformoterol is primarily used for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not approved for asthma treatment due to the increased risk of asthma-related death associated with LABA monotherapy. Additionally, it is not indicated for acute bronchospasm or rescue therapy.Â
Frequency defined:Â Â Â
1%-10%Â
Chest pain (2%)Â
Anxiety (2%)Â
HeadacheÂ
Voice disorderÂ
DiarrheaÂ
PruritisÂ
Skin rashÂ
Muscle crampsÂ
TremorÂ
Abdominal painÂ
VomitingÂ
NauseaÂ
Fever  Â
<1%:Â
Angina pectoris Â
Cardiac arrhythmiaÂ
CoughÂ
DermatitisÂ
FatigueÂ
Variable blood pressureÂ
RestlessnessÂ
Nervousness Â
Â
None
Contraindication:Â
Known hypersensitivityÂ
Caution:Â
Cardiovascular disordersÂ
Seizure disordersÂ
ThyrotoxicosisÂ
DiabetesÂ
Pregnancy consideration: It may interfere with uterine contractility. arformoterol is an enantiomer of formoterol.Â
Lactation: Excretion of arformoterol in breast milk is not known. Â
Pregnancy category:Â
Â
Pharmacokinetics:Â
Arformoterol is a long-acting beta-2 adrenergic agonist (LABA) and the (R,R)-enantiomer of formoterol, which is the pharmacologically active isomer. It acts by selectively binding to beta-2 adrenergic receptors located in the bronchial smooth muscle, leading to activation of adenylate cyclase, increased cyclic AMP (cAMP) levels, and subsequent relaxation of airway smooth muscle. This results in bronchodilation, improved airflow, and reduced airway resistance.Â
AbsorptionÂ
Arformoterol reaches its peak plasma concentration within approximately 0.5 to 3 hours after administration, with a peak plasma level of around 4.3 pg/mL. The area under the concentration-time curve (AUC) is approximately 34.5 pg·hr/mL, reflecting the overall drug exposure over time.Â
DistributionÂ
Arformoterol is moderately bound to plasma proteins, with approximately 52% to 65% of the drug bound in circulation.Â
MetabolismÂ
Arformoterol is primarily metabolized through glucuronidation by uridine diphosphoglucuronosyltransferases (UGTs) and to a lesser extent by cytochrome P450 enzymes, specifically CYP2D6 and CYP2C19, via O-demethylation.Â
Excretion and EliminationÂ
Arformoterol is primarily excreted through the urine (67%), with a smaller portion eliminated in the feces (22%). It has an elimination half-life of approximately 26 hours.Â
Arformoterol is administered via inhalation using a nebulizer. It is supplied as a solution for nebulization. The medication should be used with a standard jet nebulizer connected to an air compressor capable of delivering a consistent mist. Patients should be instructed not to swallow the solution and to avoid mixing it with other drugs unless directed by a healthcare provider.Â
Patient information leafletÂ
Generic Name: arformoterol Â
Pronounced: AR-for-MOE-ter-olÂ
Why do we use arformoterol ?Â
Arformoterol is used for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It helps improve lung function, reduce symptoms such as wheezing and breathlessness, and enhance overall quality of life in individuals with moderate to severe COPD. Arformoterol is not approved for the treatment of asthma and should not be used for acute symptom relief or as rescue therapy.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
